Kingworld Medicines Group Limited, an investment holding company, primarily engages in the distribution and sale of branded imported pharmaceutical and healthcare products. The company offers products for relieving cough, alleviating phlegm, soothing asthma, enhancing respiratory system, aiding digestion, promoting intestinal health, activating blood circulation, relieving pain, combating flu, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kingworld Imada Red Flower Oil, Culturelle probiotics product series brands. It also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices; and supplies pharmaceuticals, healthcare, general foodstuffs, and medical products. In addition, the company is involved in the distribution and sale of artwork; organization of art exhibitions; distribution and sale of Chinese medicine; and engages in technology transfer and property investment activities. It serves the People’s Republic of China, Japan, the United States, Canada, Hong Kong, Taiwan, Thailand, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People’s Republic of China.
Metrics to compare | 1110 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1110PeersSector | |
---|---|---|---|---|
P/E Ratio | 7.5x | 14.2x | −0.5x | |
PEG Ratio | 0.62 | −0.26 | 0.00 | |
Price/Book | 0.5x | 1.0x | 2.6x | |
Price / LTM Sales | 0.3x | 0.6x | 3.0x | |
Upside (Analyst Target) | - | 24.1% | 54.1% | |
Fair Value Upside | Unlock | 23.8% | 8.7% | Unlock |